CytoMed Therapeutics Limited

The momentum for this stock is not very good. Tradey thinks it is not wise to invest in CytoMed Therapeutics Limited.

News

CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 0.7%

Ticker Report CytoMed Therapeutics Limited (NASDAQ:GDTC - Get Free Report) dropped 0.7% during mid-day trading on Friday . The company traded as low as $1.45 and last traded at $1.48. Approximately 2,369 shares...\n more…

Cytomed Therapeutics acquires cord blood bank license, assets

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta ( ) T Cells Technology for Solid and Liquid

Globe Newswire Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell ("iPSC")-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells...\n more…

Short Interest in CytoMed Therapeutics Limited (NASDAQ:GDTC) Increases By 9.9%

Ticker Report CytoMed Therapeutics Limited (NASDAQ:GDTC - Get Free Report) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 38,800...\n more…

CytoMed Therapeutics Limited (NASDAQ:GDTC) Short Interest Up 9.9% in June

Zolmax CytoMed Therapeutics Limited (NASDAQ:GDTC - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling...\n more…

CytoMed Therapeutics (NASDAQ:GDTC) Given Speculative Buy Rating at Benchmark

Ticker Report Benchmark reissued their speculative buy rating on shares of CytoMed Therapeutics (NASDAQ:GDTC - Free Report) in a research note issued to investors on Tuesday, Benzinga reports. They currently have...\n more…